PreMD to sell Prevu LT for cardiovascular care in Europe

By Elaine Rigoli

Tampa, Fla., Sept. 18 - PreMD, Inc. has received CE Mark approval for its Prevu LT Skin Sterol Test as a risk assessment tool for cardiovascular disease.

The CE Mark results in a milestone payment to PreMD from its marketing partner, McNeil Consumer Healthcare.

The Toronto-based predictive medicine company said Prevu LT is a lab-processed format of the Prevu technology, which has been developed for use within the life insurance industry and diagnostic laboratories.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.